Covid-19 vac­cine boost­ers earn big thumbs up, but Mod­er­na draws ire over world sup­ply; What's next for Mer­ck’s Covid pill?; The C-suite view on biotech; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

You may re­mem­ber that at the be­gin­ning of this year, End­points News set a goal to go broad­er and deep­er. We are still work­ing to­wards that, and are ex­cit­ed to share that Beth Sny­der Bu­lik will be join­ing us on Mon­day to cov­er all things phar­ma mar­ket­ing. You can sign up for her week­ly End­points Mar­ket­ingRx newslet­ter in your read­er pro­file.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.